Vascular cancers are malignancies that arise from the cells lining blood vessels or lymphatic channels, and they account for a remarkably small share of all cancers. Even within soft-tissue sarcomas, tumors showing blood-vessel-cell origin represent under 1% of diagnoses.1PubMed. Malignant vascular tumors–an update That rarity makes them easy to overlook, hard to study in large trials, and frequently misdiagnosed. The three main types are angiosarcoma, epithelioid hemangioendothelioma, and Kaposi sarcoma, each with a distinct biology and clinical personality that shapes how it is detected and treated.
The Major Types of Vascular Cancer
Vascular cancers are not a single disease. They share an origin in endothelial cells, the thin layer of cells that lines every blood vessel, but from there they diverge sharply in how aggressive they are, where they show up, and what drives them.
Angiosarcoma is the most aggressive of the group. It can appear almost anywhere in the body, though it most commonly shows up as a skin lesion on the head and neck of older men.1PubMed. Malignant vascular tumors–an update It also arises in the liver, heart, spleen, and breast. What makes angiosarcoma particularly dangerous is its tendency to grow fast and spread early. Hepatic angiosarcoma, for example, accounts for roughly 2% of primary liver cancers and is marked by rapid progression and vague symptoms that make catching it early very difficult.2Radiology Case Reports. Hepatic angiosarcoma: A challenging diagnosis Cardiac angiosarcoma behaves similarly: abnormal blood vessels invade the heart muscle itself, destroying healthy tissue as they expand.3PubMed Central. Primary Cardiac Angiosarcoma: A Review
Epithelioid hemangioendothelioma (EHE) sits in an unusual middle ground. It is malignant, it can invade surrounding tissue, and it can metastasize, but it often behaves far more indolently than angiosarcoma. EHE most commonly appears in the liver, lungs, and bones, though it has been documented at many other sites.4PubMed. A Review of the Spectrum of Imaging Manifestations of Epithelioid Hemangioendothelioma Some patients live for years with stable disease that requires only monitoring, while others experience progressive spread. EHE is defined at the molecular level by specific gene rearrangements involving either WWTR1 or YAP1, and the particular fusion present can influence the tumor’s behavior.5PubMed Central. YAP1::TFE3 mediates endothelial-to-mesenchymal plasticity in epithelioid hemangioendothelioma
Kaposi sarcoma (KS) is driven by a specific virus, Kaposi’s sarcoma-associated herpesvirus (KSHV, also called HHV-8). The virus infects endothelial cells and hijacks their growth signals, pushing them toward uncontrolled proliferation.6PubMed Central. Kaposi’s sarcoma herpesvirus/ Human herpesvirus-8 (KSHV/HHV8), and the oncogenesis of Kaposi’s sarcoma KS typically shows up as purple or reddish-brown skin patches or nodules, but it can also involve the mouth, lymph nodes, lungs, and gastrointestinal tract.
What Causes These Cancers
Each vascular cancer type has its own set of risk factors, but a few themes recur: radiation exposure, immune suppression, and chronic tissue damage.
For angiosarcoma, previous radiation therapy is a well-established trigger. Women treated with radiation for breast cancer, for instance, face a small but real risk of developing angiosarcoma in the irradiated field years later. Radiation-induced angiosarcomas frequently show amplification of the MYC gene, a molecular signature that helps pathologists distinguish them from new primary tumors.1PubMed. Malignant vascular tumors–an update Chronic lymphedema is another recognized cause. Stewart-Treves syndrome, first described in 1948, refers specifically to angiosarcoma arising in a limb with longstanding lymphedema, most classically after radical mastectomy.7Geriatric Care. Stewart-Treves syndrome: a case report of lymphedema-related angiosarcoma Cutaneous angiosarcoma of the scalp, the most common presentation overall, tends to affect elderly men and is linked to chronic sun exposure.
For Kaposi sarcoma, KSHV infection is the necessary ingredient, but the virus alone is not sufficient. Most people who carry KSHV never develop KS. The disease emerges when the immune system is compromised. The AIDS epidemic brought this into sharp focus. In the early 1980s, disseminated KS appeared in homosexual men in New York and California, and at its peak, over 40% of men with AIDS developed it. By the late 1980s, that figure had already dropped below 20%, and the widespread use of antiretroviral therapy has lowered it further since.8Journal of the American Academy of Dermatology. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi’s sarcoma KS also occurs in organ transplant recipients on immunosuppressive drugs and, in a milder “classic” form, in elderly men of Eastern European or Mediterranean descent.
EHE does not have well-established environmental risk factors in the way angiosarcoma does. Its development appears to be driven primarily by the gene fusions that define it. The more common WWTR1-CAMTA1 fusion produces the typical form of EHE, while a less common YAP1-TFE3 fusion defines a distinct variant that tends to occur in younger adults.9PubMed Central. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma Both fusions disrupt the Hippo signaling pathway, a cellular growth-control system whose malfunction plays a role in many types of cancer.10Modern Pathology. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases
Symptoms and Why Diagnosis Is Difficult
One of the most frustrating aspects of vascular cancers is how nonspecific the symptoms tend to be. There is no single alarm bell that reliably signals the presence of a tumor growing from blood vessel cells.
Cutaneous angiosarcoma, the most visible form, often starts as a bruise-like discoloration or a raised, bleeding lesion on the scalp or face. It can look like a simple wound that will not heal, or even like a skin infection, which is why patients sometimes go months before getting a biopsy. Internal angiosarcomas are harder still. Hepatic angiosarcoma may first appear as vague right-sided abdominal pain and dizziness, and initial imaging can suggest other conditions entirely.2Radiology Case Reports. Hepatic angiosarcoma: A challenging diagnosis Splenic angiosarcoma has been reported to metastasize to the liver and heart, showing up on imaging as unevenly enhancing masses.11PubMed Central. Splenic angiosarcoma with hepatic and cardiac metastases: a case report and literature review
Kaposi sarcoma is somewhat easier to recognize visually because of its characteristic dark skin lesions, but visceral KS involving the lungs or gut can cause cough, bleeding, or bowel obstruction without any skin signs at all. The psychological burden of visible KS lesions is also substantial; patients with prominent or visceral disease report significantly worse mental health and coping.12PubMed. Quality of life of patients with Kaposi Sarcoma: a cross-sectional study
EHE can be discovered incidentally on imaging performed for other reasons, especially when it involves the liver. Because it grows slowly, some patients have no symptoms at all until the disease is quite advanced.
Tumors That Masquerade as Other Conditions
Vascular cancers are notorious mimics. A pulmonary artery intimal sarcoma, for instance, grows inside the wall of the pulmonary artery and can look exactly like a blood clot on imaging. Patients present with shortness of breath, chest pain, and cough, all of which are textbook signs of a pulmonary embolism. On contrast-enhanced CT, the tumor appears as a filling defect in the artery, though it tends to be more lobulated and unilateral than a true clot and may expand the artery’s diameter.13PubMed Central. An intimal sarcoma of pulmonary artery mimicking pulmonary embolism: a case report and literature review Cardiac intimal sarcoma presents similarly, sometimes triggering heart failure, abnormal heart rhythms, or even stroke before anyone suspects a tumor. About a quarter of patients in one series had distant metastases, most commonly to the brain, intestine, and bone.14PubMed Central. Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role of MDM2 Amplification/Co-Amplification and MDM2 Immunostaining
On the benign side of the spectrum, anastomosing hemangioma is a rare vascular lesion that looks under the microscope like it could be angiosarcoma. It has irregular, branching blood-filled channels, but the cells lining them lack the aggressive features of a malignancy. Recognizing it correctly is important because misdiagnosis could lead to unnecessary radical surgery.15PubMed. Anastomosing Hemangioma: Short Review of a Benign Mimicker of Angiosarcoma Glomangiosarcoma, the malignant form of a glomus tumor, is another extreme rarity; less than 1% of all glomus tumors turn out to be malignant, and diagnosis requires careful pathological examination.16PubMed Central. A case of malignant glomus tumor (glomangiosarcoma) of the nasal cavity
How Vascular Cancers Are Diagnosed
A tissue biopsy is ultimately required for a definitive diagnosis. Pathologists rely on special staining to confirm that a tumor is vascular in origin. The key markers are proteins found on endothelial cells. ERG and CD31 are the two most sensitive markers for identifying blood vessel tumors, and using both together strengthens the diagnosis because ERG stains the nucleus of the cell while CD31 stains the cell membrane, providing complementary visual information. CD34 is also used but is somewhat less sensitive.17PubMed. The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases A known diagnostic trap is that angiosarcoma can sometimes aberrantly express markers associated with other tumor types, potentially steering pathologists down the wrong track. Additional staining for CD31, ERG, and FLI1 helps resolve these ambiguous cases.18PubMed. Aberrant expression of neuroendocrine markers in angiosarcoma: a potential diagnostic pitfall
Molecular testing is increasingly essential, especially for EHE. Confirming the WWTR1-CAMTA1 or YAP1-TFE3 fusion not only nails the diagnosis but also indicates the subtype, which has implications for expected behavior.9PubMed Central. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma For intimal sarcomas of the heart, amplification of the MDM2 gene serves as a core diagnostic feature, and detection strategies have been refined to layer imaging, immunohistochemistry, and molecular analysis together.14PubMed Central. Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role of MDM2 Amplification/Co-Amplification and MDM2 Immunostaining
PET/CT scanning, which highlights areas of high metabolic activity, has shown promise for staging angiosarcoma. It can reveal the full extent of disease across multiple sites and detect bone involvement that might otherwise be missed. Early evidence also suggests it could eventually help track treatment response and catch recurrences.19PubMed. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp
Treatment of Angiosarcoma
Surgery remains the cornerstone of treatment when the tumor can be removed. Wide excision with clear margins offers the best chance of local control, though angiosarcoma’s tendency to spread along tissue planes means that achieving truly clear margins is often challenging. Radiation therapy is frequently added after surgery, especially for cutaneous disease of the head and scalp, where microscopic disease at the edges is common.
Chemotherapy is used for advanced or metastatic angiosarcoma. Taxane-based regimens, particularly paclitaxel, are a standard choice. A phase II trial tested paclitaxel combined with bevacizumab, a drug that blocks the growth of new blood vessels, in patients with metastatic or unresectable angiosarcoma. The combination produced an overall median survival of 16 months and a median progression-free survival of about 5 months, with about two-thirds of patients not progressing at the four-month mark.20Journal of Clinical Oncology. A phase II trial of Q3 week or weekly paclitaxel in combination with bevacizumab for metastatic or unresectable angiosarcoma The toxicity profile was manageable but not trivial, with low white blood cell counts being the most common serious side effect.
Immune checkpoint inhibitors have emerged as a genuinely exciting development. In an early case series, five of seven angiosarcoma patients treated with checkpoint inhibitors showed partial responses at 12 weeks, and one patient achieved a complete response.21PubMed Central. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution Larger retrospective data have reinforced these findings, with pembrolizumab in particular showing durable activity.22PubMed. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study The strongest responses appear to come from angiosarcomas in sun-exposed areas, which tend to carry a high number of mutations and thus more targets for the immune system to recognize. Researchers are working to identify biomarkers such as PD-L1 expression and tumor mutational burden that could predict which patients are most likely to benefit, and combinations of checkpoint inhibitors with anti-angiogenic drugs are in active clinical trials.23PubMed Central. Novel Therapeutic Approaches for Cutaneous Angiosarcoma, Particularly Focusing on Immune Checkpoint Inhibitors
Treatment of Kaposi Sarcoma
Because AIDS-related KS is fundamentally driven by immune suppression, the backbone of treatment is antiretroviral therapy (ART). Restoring immune function allows the body to regain some control over KSHV, and many patients with limited skin disease see improvement with ART alone. However, ART by itself is not always enough. In a randomized trial comparing ART plus pegylated liposomal doxorubicin to ART alone for moderate-to-advanced KS, the combination group achieved response rates of 76% compared to 20% with ART alone after 48 weeks.24PubMed. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi’s sarcoma
Even patients whose disease looks limited on the skin may need chemotherapy added to ART if the lesions are nodular in form, which tends to predict a worse course.25PubMed Central. Antiretroviral Therapy for HIV-Associated Cutaneous Kaposi’s Sarcoma: Clinical, HIV-Related, and Sociodemographic Predictors of Outcome For transplant-related KS, reducing the dose of immunosuppressive drugs, when safely possible, is the equivalent first step. Classic KS in elderly patients tends to run a more indolent course, and treatment decisions are guided more by symptoms and cosmetic impact than by the tumor itself threatening life.
Quality of life is a major consideration. Before starting ART, KS patients in one study scored lower than non-KS HIV patients on most measures of well-being. After 48 weeks of treatment, those differences largely resolved, and KS patients actually scored higher in several quality-of-life domains.26PubMed Central. Impact of Kaposi Sarcoma on Quality of Life Amongst HIV-infected Adults Initiating Antiretroviral Therapy in East Africa Still, the psychological toll of visible lesions persists even when physical health stabilizes, highlighting the need for mental health support as part of KS care.12PubMed. Quality of life of patients with Kaposi Sarcoma: a cross-sectional study
Pediatric Vascular Tumors
Vascular tumors are not exclusively an adult problem. Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that appears in infants and young children. It is locally aggressive and can trigger a dangerous clotting complication in which platelets become trapped within the tumor, causing both severe clotting within the lesion and paradoxical bleeding elsewhere due to platelet depletion. Diagnosis requires a combination of clinical appearance, imaging, and tissue examination. Treatment is tailored to the individual child based on tumor size, location, symptoms, and complications.27PubMed. Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma KHE is not the same disease as the common infantile hemangioma, which nearly always resolves on its own, and distinguishing between the two early matters because KHE requires active intervention.
What Dogs Are Teaching Us About Human Angiosarcoma
One of the more unexpected research paths in vascular oncology involves dogs. Hemangiosarcoma, a tumor of blood vessel cells, is relatively common in certain large dog breeds and is one of the most aggressive cancers in veterinary medicine. Most dogs die within months of diagnosis despite chemotherapy. What makes this relevant to human patients is that the genetic landscape of canine hemangiosarcoma closely mirrors that of human angiosarcoma, particularly in breast and visceral subtypes. The same genes and signaling pathways carry mutations in both species.28PubMed Central. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma
Molecular subtyping has reinforced the parallels further. Canine hemangiosarcoma carries driver mutations in genes like NRAS, PIK3CA, PLCG1, and TP53, and activation of the MAPK and PI3K pathways appears central to tumor growth in both dogs and humans.29PubMed Central. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma Because dogs develop these tumors naturally and frequently, they provide something human oncology desperately needs for rare cancers: enough cases to run clinical trials. Experimental therapies can be tested in dogs with naturally occurring hemangiosarcoma on a timeline and at a scale that would take decades with human angiosarcoma patients. The survivorship rate with current treatments sits around 12% in dogs, making any improvement meaningful and measurable.30Journal of Oncology Research and Therapy. Survivorship Endpoints in Pet Dogs with Naturally Occurring Cancer as Models for Human Cancer This comparative oncology approach is increasingly seen as a way to accelerate the development of targeted therapies that could eventually benefit both species.